[PRNewswire] Caprion-HistoGeneX Acquires Clinical Logistics Inc., a Virtual
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Central Specimen Management CRO, and Expands its Support of Clinical Trials Specimen Logistics
(MONTREAL, Jan. 7, 2021 PRNewswire=연합뉴스) Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners, announced today the acquisition of Clinical Logistics Inc. ("CLI"), a Virtual Central Specimen Management CRO based in Halifax, Canada. The acquisition enables Caprion-HistoGeneX to broaden its specimen logistics services to support the global clinical trial needs of its pharma and biotech customers better. Focused on critical specialty specimens with complex processing requirements such as limited stability and/or real-time testing needs, CLI offers integrated, customizable solutions combined with kitting and specimen logistic services for timely specimen delivery.
CLI was founded in 2002 and has supported clinical trials in over 50 countries. The company has earned a reputation for quality and customer service excellence with some of the largest pharmaceutical companies, biotechs and CROs. Answering an unmet need in the marketplace for high quality handling of critical samples from clinical trial sites to the laboratory, CLI is positioned as a key player in clinical trial logistics with a focus on specialty specimens. CLI's services also include logistics and kitting for pharmacokinetic / pharmacodynamic (PK/PD) and pharmacogenomics (PG) biomarkers. "We are excited to be a part of the Caprion-HistoGeneX organization. CLI will be able to leverage the broad capabilities and global footprint of Caprion-HistoGeneX to continue to improve and rapidly globalize our Central Specimen Management services" said Raymond Mah, Co-CEO and Co-Founder of CLI.
Recently recommended for ISO 13485 certification, CLI offers customized specimen collection kits, shipment assistance at investigator sites, as well as timely specimen shipping coordination & tracking, resulting in high recovery of specialty specimens from investigator sites, optimal specimen integrity and timely analyses. With its Virtual Central Specimen Management platform, CLI eliminates the need for investigator sites to transfer specimens to a central storage facility before their arrival at third-party testing labs. As a centralized point of contact during clinical trials, CLI increases specimen handling consistency and minimizes the burden of specimen tracking discrepancies.
"Caprion-HistoGeneX is excited to expand its specimen logistics and management solutions, reinforcing our end-to-end services and ensuring specimen integrity from collection to analysis. These services will be scaled through our worldwide network of laboratories to provide comprehensive support to global clinical trial sites and help alleviate common daily challenges that our clients are facing with their complex clinical operations." said Martin LeBlanc, CEO of Caprion-HistoGeneX.
About Caprion-HistoGeneX
Caprion-HistoGeneX is a leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics, and genomics, Caprion-HistoGeneX supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 8 facilities located in Canada, USA, Belgium, Australia, and China.
For more information: www.caprion.com and www.histogenex.com
About Clinical Logistics Inc.
Clinical Logistics Inc. (CLI) is a contract research organization (CRO) providing clinical trial services to global pharmaceutical and biotech companies. The services include the provision of specimen collection supplies, production of customized specimen identification labels and kits, and specimen shipping coordination, management, and tracking.
For more information: www.clinicallogistics.net
About Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle-market healthcare and industrials companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, has completed more than 200 platform and add-on investments, and achieved more than 30 realizations. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add.
For more information: www.arsenalcapital.com
Logo - https://mma.prnewswire.com/media/1396104/Caprion_Biosciences_Caprion_HistoGeneX_Logo.jpg
Caprion-HistoGeneX Logo
Logo - https://mma.prnewswire.com/media/1396106/Caprion_Biosciences_Caprion_ClinicalLogistics_Logo1.jpg
Clinical Logistics Inc. Logo
Source: Caprion Biosciences Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- '빅5' 초유의 전면 휴진 가능성…환자 불편·경영난 악화 불보듯 | 연합뉴스
- '약자 복지' 강조한 尹대통령, 이재명과 '약자만 선별지원' 논의하나 | 연합뉴스
- 與 "입법 독재" 野 "총선 민심"…5월 국회 앞두고 정면 대치 | 연합뉴스
- 법무부, 尹대통령 장모 가석방 여부 다음 달 8일 재심사 | 연합뉴스
- 2월 출생아 첫 2만명선 하회…설날 영향에 결혼 5%↓ | 연합뉴스
- 우리나라 취업자 중 대졸 이상 학력자 '절반 처음 넘었다' | 연합뉴스
- 국산 초소형 군집위성 1호기 발사체서 정상 분리…궤도 투입 (종합) | 연합뉴스
- 후쿠시마 제1원전, 정전으로 오염수방류 중지…"방사선량 정상"(종합) | 연합뉴스
- 민주, 조국당 견제하나…'범야권 연석회의' 曺제안 사실상 거절 | 연합뉴스
- 추미애 "민주당 출신 국회의장이 다 된 밥에 코…폼 재면 안돼" | 연합뉴스